The invention relates to a compound of general formula : (I) wherein A is selected from the groups (a), (b) or (c): formula (II) or formula (III) (b) or is cycloalkyl, (c) optionally substituted by lower alkyl (c)Ar1 is phenyl or a six membered heteroarylX1 is N or CH X2 is N-R1 or O R1 is S(O)2-lower alkyl, C(O)-cycloalkyl substituted by lower alkyl, or is C(O)-lower alkyl, lower alkyl, cyano, cycloalkyl or is a six membered heteroaryl substituted by lower alkyl, cyano, C(O)-lower alkyl, halogen, lower alkyl substituted by halogen or lower alkoxy or is phenyl substituted by cyano or halogen R2 is lower alkyl, halogen, pyrazolyl, 3-methyl-[1,2,4]oxazolyl, 5-methyl-[1,2,4]oxadiazol-3-yl, pyridyl substituted by cyano, or is phenyl substituted by halogen, or is cyano, lower alkoxy, or is piperidin-2-one or to pharmaceutically active salts, sterioisomeric forms, including individual diastereoisomers and enantiomers of the compound of formula I as well as racemic and non-racemic mixtures thereof..It has been found that the present compounds are high potential NK-3 receptor antagonists for the treatment of depression, pain, psychosis, Parkinsons disease, schizophrenia, anxiety and attention deficit hyperactivity disorder (ADHD).Linvention concerne un composé de formule générale : (I) dans laquelle A est choisi dans les groupes (a), (b) ou (c) : formule (II) ou formule (III) (b) ou est cyclo-alkyle, (c) facultativement substitué par un alkyle inférieur (c) Ar1 est phényle ou un hétéro-aryle à six chaînons X1 est N ou CH X2 est N-R1 ou O R1 est S(O)2-alkyle inférieur, C(O)-cycloalkyle substitué par un alkyle inférieur ou est C(O)-alkyle inférieur, alkyle inférieur, cyano, cyclo-alkyle ou est un hétéro-aryle à six chaînons substitué par un alkyle inférieur, cyano, C(O)-alkyle inférieur, halogène, alkyle inférieur substitué par un halogène ou alkoxy inférieur ou est phényle substitué par cyano ou halogène R2 est alkyle inférieur, halogène, pyrazolyle, 3-méthyl-[1-2-4]ox
